Overview
ACOTEC-B (6669)
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China...
- Open
- 4.500
- High
- 4.600
- Low
- 4.400
- Prev. Close
- 4.610
- Volume
- 615.00K
- Turnover
- 2.78M
- Avg Price
- 4.514
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 4.34%
- 52wk High
- 15.320
- Volume Ratio
- 1.68
- Turnover Ratio
- 0.20%
- 52wk Low
- 4.400
- HK Mkt Cap
- 1.41B
- Market CapHKD
- 1.41B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.185
- EPSDynamic
- -0.594
- EPSStatic
- --
- BVPS
- 5.13
- P/B
- 0.87
- HK Shares
- 313.39M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 313.39M
- Min lot size
- 1,000
- Currency
- HKD
ACOTEC-B Analyst Rating
View moreForecast & Rating
Mar 30, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 13
Acotec Scientific (6669.HK) closed at HK$4.61, down roughly 8% from the prior close of HK$5.01, in a spike-and-fade session: it touched HK$5.035 at 11:10 BJ before sliding to HK$4.65 by 15:45, on 562,000 shares and HK$2.78 million turnover, a thin 0.18% turnover rate. The move extends a year-long slide: the stock is down 66.42% year-to-date and 69.91% below its 52-week high of HK$15.32 set on 13 January, now trading under both its MA20 of HK$5.385 and MA60 of HK$5.889 while printing a fresh 52-week low. Fundamentals add pressure: H1 FY26 revenue fell 5.6% to RMB331.58 million and the company swung to a net loss of RMB80.83 million, with Q2 EPS of -HK$0.1559, a -24.38% net margin and a PE of -24.98x. Still, Q2 operating profit rose 18.02% to HK$50.07 million and price-to-book stands at 0.90x, so the operating line has not deteriorated in step with the bottom line.
- Nov, 10
Acotec Scientific reversed an early gain to close down 3.7% at HK$5.165, having touched HK$5.385 in the morning session before sliding to a HK$5.055 intraday low late in the afternoon on 633,000 shares and a 0.2% turnover rate. The overhang traces to interim results: revenue of RMB331.58 million, down 5.6%, and a net loss of RMB80.83 million versus prior-year profit, driven by a RMB150 million impairment after terminating US clinical programmes; second-quarter net loss reached HK$46.68 million, down 196% year on year, with ROE at -11.58%, while operating profit rose 18% to HK$50.07 million, a contrast that has not reached the bottom line. The stock is down 62.4% year to date, 66.3% below its 52-week high of HK$15.32, and only 4.2% above the HK$4.955 low set on 2 November; at HK$5.165 it sits under its MA20 of 5.521 and MA60 of 5.952, with PB 1.01 and a negative PE. Single-day moves of 6% to 7% have recurred since late October, though operating profit growth has yet to translate into net profit.
- Nov, 9
Acotec Scientific extended its pullback as investors kept digesting the first-half swing to a net loss, spiking to HK$5.50 at the open — the session high — before sliding to an intraday low of HK$5.03; the latest HK$5.365 sits about 3.3% below the prior close of HK$5.55. The company guided for an H1 net loss of up to RMB 80.83 million, including roughly RMB 150 million of provisions tied to terminated US clinical programmes, while interim revenue fell 5.6% to RMB 331.58 million. Quarterly revenue of HK$191 million was broadly flat year on year and operating profit rose 18%, yet a net loss of HK$46.68 million and EPS of -HK$0.156 show cost pressure still biting. The shares are down 60.9% year to date and 65% below the HK$15.32 high of 13 January, trading under both the 5.557 MA20 and 5.978 MA60 and only 8.3% above the 2 November low of HK$4.955, with PB at 1.05x. A near-7% rebound on 4 November, though, points to some support near the lows.
- Nov, 6
Acotec Scientific traced a dip-then-rebound path and was lifted into the close at HK$5.55, up 0.09%: it slipped from HK$5.545 to HK$5.330 in the morning session, spiked to HK$5.600 at 14:00 BJ, sank to HK$5.250 at 15:43 and then recovered, on 632,000 shares and HK$3.42 million turnover, a thin 0.20% turnover rate. The overhang remains the interim report: first-half revenue of RMB331.58 million fell 5.6% year on year and the net result swung to a RMB80.83 million loss, driven by a RMB150 million impairment after terminating US clinical projects; Q2 EPS was -HK$0.1559 and net profit -HK$46.68 million, down 196% year on year. The stock is down 59.58% year to date, 63.77% below its 13 January 52-week high of HK$15.32 and only 12% above the 2 November low of HK$4.955, while HK$5.55 sits under the MA20 of HK$5.588 and MA60 of HK$5.997, with PB at 1.08. Though Q2 operating profit rose 18.02% to HK$50.07 million.
- Nov, 4
Acotec Scientific (6669.HK) opened at its 5.10 HKD session low and ground higher to 5.355 HKD by 15:20 BJ before closing at 5.34 HKD, up 4.4%, on 611,000 shares and roughly 3.19 million HKD of turnover, a thin 0.19% turnover-rate rebound rather than a volume-backed reversal. The move follows a fresh 52-week low of 4.955 HKD on 2 November, leaving the stock 65.14% below its 13 January high of 15.32 HKD and down 61.11% year to date, still under the MA20 of 5.615 and the MA60 of 6.073. Fundamentals cut the other way: first-half revenue fell 5.6% to RMB 331.58 million and impairment from terminated U.S. clinical programmes drove a net loss of RMB 80.83 million, while Q2 operating profit of 50.07 million HKD rose 18.02% year on year even as net margin slid to -24.38%, with PB at 1.04 and PE negative. Trading flow rather than earnings drove the session, though the losses and the overseas retreat show no sign of reversing.
News
Market Movers · Acotec hits 52-week low
Quartr · CoTec Holdings: Project milestones advanced alongside losses, a $20M financing, and execution risks
businessinsider · CoTec Holdings reports Q3 results
StockTitan · CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary | CTHCF Stock News
Market Movers · Acotec climbs nearly 7% in Hong Kong trading
